This study revealed a novel mechanism of circKIF20B/miR-615-3p/MEF2A signaling axis involving progression of gefitinib resistance in NSCLC.
Exosome-derived circKIF20B suppresses gefitinib resistance and cell proliferation in non-small cell lung cancer.